Related references
Note: Only part of the references are listed.Universal Prophylaxis is Cost Effective in Cytomegalovirus Serology-Positive Kidney Transplant Patients
Fu L. Luan et al.
TRANSPLANTATION (2011)
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies
Tomas Reischig
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation
Camille N. Kotton et al.
TRANSPLANTATION (2010)
Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States
Emily A. Blumberg et al.
TRANSPLANTATION (2010)
Cytomegalovirus in Solid Organ Transplant Recipients
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Six-Month Prophylaxis Is Cost Effective in Transplant Patients at High Risk for Cytomegalovirus Infection
Fu L. Luan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Effect of Cytomegalovirus Viremia on Subclinical Rejection or Interstitial Fibrosis and Tubular Atrophy in Protocol Biopsy at 3 Months in Renal Allograft Recipients Managed by Preemptive Therapy or Antiviral Prophylaxis
Tomas Reischig et al.
TRANSPLANTATION (2009)
Influence of time of rejection on long-term graft survival in renal transplantation
Gerhard Opelz et al.
TRANSPLANTATION (2008)
Medical progress: Infection in solid-organ transplant recipients
Jay A. Fishman
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk
Solbjorg Sagedal et al.
CLINICAL TRANSPLANTATION (2007)
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients
J. A. Khoury et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection
T Reischig et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients
ID Pavlopoulou et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection
T Reischig et al.
TRANSPLANTATION (2005)
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
C Paya et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival
S Sagedal et al.
KIDNEY INTERNATIONAL (2004)
A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation
DP Tilden et al.
CLINICAL TRANSPLANTATION (2004)
Resource use and treatment costs after kidney transplantation:: Impact of demographic factors, comorbidities, and complications
EG Hagenmeyer et al.
TRANSPLANTATION (2004)
The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis
MA Schnitzler et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
The economic value of valacyclovir prophylaxis in transplantation
JP Squifflet et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients
S Sagedal et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2002)
Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation.
CM Legendre et al.
TRANSPLANTATION (2000)
The economic impact of cytomegalovirus infection after liver transplantation
WR Kim et al.
TRANSPLANTATION (2000)